NO produces arteriolar flow-induced dilation (FID) in healthy subjects but is replaced by mitochondria-derived hydrogen peroxide (mtH 2 O 2 ) in patients with coronary artery disease (CAD). Lysophosphatidic acid (LPA) is elevated in patients with risk factors for CAD, but its functional effect in arterioles is unknown. We tested whether elevated LPA changes the mediator of FID from NO to mtH 2 O 2 in human visceral and subcutaneous adipose arterioles.
Introduction
Endothelial cells form an interface between circulating blood and surrounding tissue and actively respond to changes in blood flow. The endothelium-dependent, flow-stimulated release of NO and other vasodilator factors that act on adjacent vascular smooth muscle cells (VSMC) is a key means by which human resistance arterioles dilate and increase tissue perfusion (flow-induced dilation; FID). Endothelial release of NO promotes vascular health by reducing inflammation and proliferation (Kim et al., 2008) . Previous studies demonstrated that the magnitude of FID is preserved in arterioles from patients with coronary artery disease (CAD) or multiple risk factors for CAD, but the mediator switches from NO to proinflammatory and atherogenic mitochondrial hydrogen peroxide (mtH 2 O 2 ) (Liu et al., 2003; Beyer et al., 2017) , providing a potential pathway underlying the microvascular contributions to CAD. We have previously reported intracellular components involved in the transition from NO to H 2 O 2 , including PGC-1α (Kadlec et al., 2017) and telomerase (Beyer et al., 2016) . The upstream cell-surface activators of this transition, however, remain incompletely characterized. Understanding what factors and receptors act at the endothelial cell surface of arterioles is essential for constructing a complete signalling pathway and identifying novel targets to reduce H 2 O 2 release in the context of CAD.
Lysophosphatidic acid (LPA), a simple phospholipid, is an autacoid found at the cell surface and in the circulation. LPA triggers a plethora of cellular responses ranging from enhanced proliferation, migration and invasiveness to morphological changes, increased permeability or apoptotic cell death in different cells of the vasculature (Siess et al., 1999; van Nieuw Amerongen et al., 2000; Lin et al., 2006; Panchatcharam et al., 2008) . Physiological concentrations range from nM to μM levels (Aoki, 2004) and are controlled by a dynamic balance of synthesis (mainly by secreted autotaxin) (Albers et al., 2010; Gierse et al., 2010) and degradation [primarily by membrane-bound ecto-activity of lipid phosphate phosphatase 3 (LPP3)] (Tanyi et al., 2003; Panchatcharam et al., 2014) . Disruption of these control mechanisms can increase LPA levels by more than 10-fold, as reported in individuals with cancer (Baker et al., 2002) , neurological disorders or risk factors for cardiovascular disease, such as hyperlipidaemia (Dohi et al., 2012) or hypertension (Xu et al., 2003) . A rise in LPA has also been implicated in the development and progression of atherosclerosis and cardiovascular disease (Bot et al., 2013; Kurano et al., 2015; Busnelli et al., 2017) . These effects are mediated by cognate LPA receptors. Currently, there are six LPA receptors that belong to the GPCR family. Each receptor couples to at least one or more heterotrimeric G α proteins, such as G 12/13 , G q/11 , G i/o and G s and can activate a complex array of downstream signalling pathways with physiological and pathological effects on the vasculature. In particular, signalling through LPA 1 receptor is involved in many LPA-induced vascular effects, such as increased inflammation and endothelial cell migration (Panetti et al., 2000; Panetti et al., 2004) . Additionally, inhibition of LPA 1 receptor but not others reduces inflammation in cultured endothelial cells (EC) (Rizza et al., 1999) . Independent studies have shown that increased LPA, up to 10 μM, decreases endothelial NOS (eNOS) expression, reduces NO bioavailability and increases ROS production in cultured cells (Chen et al., 1995; Shin et al., 1999; Chen et al., 2012) , all hallmarks of endothelial dysfunction. However, LPA's functional influence on intact human arterioles, and the receptor responsible for these effects, has not been explored. Examining the arteriolar effects of elevated LPA is clinically relevant given the prognostic importance of arteriolar dysfunction (van de Hoef et al., 2014) .
We hypothesized that exposing arterioles from patients without CAD (non-CAD) to elevated levels of LPA (10 μM) would shift the mediator of FID away from NO to mtH 2 O 2 , reproducing the phenotype observed in arterioles from patients with CAD. Given that LPA signals through cognate LPA receptors, we further examined which receptors are expressed in human arterioles and mediate LPA's effects. We discovered that elevated levels of LPA in vessels from subjects without CAD increases mtH 2 O 2 during FID in a LPA 1 receptordependent manner. Data on patient demographics for adipose CAD and non-CAD arterioles used in the study. n = number of patients. *P < 0.05 non-CAD patients versus patients with CAD.
Methods

Tissue acquisition
were categorized as the non-CAD group. Vessels defined as CAD were obtained from tissue from subjects with clinically diagnosed CAD.
Cannulated arteriole preparation and flow-induced dilation
Human arterioles were isolated, and excess adipose and connective tissue was removed. The vessels were cannulated onto glass micropipettes of matched impedance (diameters of both pipettes per single chamber preparation did not vary by more than 2 μm and was typically kept between 35 and 45 μm, depending on the size of an arteriole) filled with Krebs buffer [(in mM) NaCl 118, KCl 4.7, CaCl 2 2.5, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 20, Na 2 EDTA 0.026, and dextrose 11, pH 7.4] and secured using sutures in an organ chamber also filled with Krebs buffer solution. The arterioles were kept at 37°C and were pressurized to 60 mmHg in a step-wise manner (30 min at 30 mmHg followed by 30 min at 60 mmHg) using a dual-reservoir system, where each micropipette is connected to its own reservoir. Once the equilibration time was reached, the vessels were constricted with endothelin-1 (ET-1) to 30-60% of the passive diameter. With stable constriction lasting ≥10 min, the vessels were exposed to increasing physiological rates of flow (pressure gradient; 5 to 100 cmH 2 O) with constant intraluminal pressure, as described previously (Kuo et al., 1990; Kuo et al., 1991; Miura et al., 2003) . Briefly, in this preparation, flow is initiated by simultaneously moving of the reservoirs in an equal and opposite direction (one down and one up by an equal distance from the starting point) to generate a pressure gradient with shear rates estimated at 5 to 25 g·cm 3 ·s À2 (dyne·cm À2 ), while preserving intraluminal pressure (Kuo et al., 1990) . In some vessels, two studies were performed in sequence separated by a wash (20 mL of Krebs buffer replaced five times) and a 30-min re-equilibration period prior to the second curve. At the end of each experiment, papaverine (100 μM) was used to assess maximal dilation. At the end of each experiment, the matched impedance of the pipettes was verified by applying max flow (100 cmH 2 O) in reverse direction for 5 min and in the presence of papaverine. If vessel diameters were different between flows of opposite direction, vessels were excluded from analysis. Additionally, vessels that did not reach or retain stable constriction for at least 10 min were excluded from the data set, as were arterioles that did not reach 75% of max dilation to papaverine.
Pharmacological intervention
All treatments were added to the organ bath (Krebs buffer) and constituted ≤1% of the total circulating volume. Vessels were treated with LPA (Abcam, Cambridge, MA, USA, ab146430; dissolved in PBS, pH 7.4, final concentration in the organ bath 10 μM) for ≥30 min (depending on experiment performed) prior to constriction. were chosen based on data published by other groups working with these antagonists in the context of vascular biology (Ruisanchez et al., 2014; Wu et al., 2015) .
Cell culture
HUVECs were purchased from ATCC (Manassas, VA, USA) and cultured on 100 mm culture plates in endothelial cell growth medium (EGM ® -2; Lonza, Basel, Switzerland) supplemented with growth factors, cytokines and 5% FCS. Human cardiac microvascular endothelial cells (HMVECs) lysates were a gift from Dr Julie Freed and prepared as previously described (Freed et al., 2017) . Briefly, cells were purchased from Lonza and cultured in 100 mm culture plates in cell growth medium (EBM-2; Lonza) supplemented with growth factors, cytokines and 10% FCS. Cells at passage 3-5 with 80-95% confluency were used.
Western blot
Vessels were isolated and connective tissue was carefully removed. Vessels were snap frozen in liquid nitrogen and stored at À80°C until further processing. Cultured endothelial cells (HUVECs) were scraped from culture dishes and centrifuged to form a cell pellet, which was then snap frozen until further processing. Three to five arterioles from each tissue were frozen and constituted one biological replicate. Four culture dishes with HUVECs and three separate cell lysate preparations of HMVECs were used. For lysate preparations, vessels were thawed and homogenized using a glass homogenizer in cold lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% deoxycholic acid, 0.1% SDS, 0.5% NP40) supplemented with a protease and phosphatase inhibitor cocktail (Roche, Basel, Switzerland) and briefly sonicated. Cell pellets were thawed and briefly sonicated. Total protein concentration was determined using BCA protein assay (Thermo Scientific, Waltham, MA, USA). Protein samples of known concentration from each tissue (patient) were subjected to 4-20% SDS-PAGE and transferred to nitrocellulose membranes. To detect target receptor protein, antibodies to LPA 1 (Abcam, ab166903; 1:1000), LPA 3 (LSBio, LS-A1014; 1:1000), LPA 3 [Abcam (Abc), ab23692, 1:1000] and GAPDH (Abcam, ab8245, 1:10 000) were used, followed by peroxidase conjugated secondary antibodies and chemiluminescent substrate (Bio-Rad, Hercules, CA, USA).
Quantitative real-time PCR
Isolated and cleaned human adipose vessels were snap frozen in liquid nitrogen and stored in À80°C until further processing. Total RNA was extracted from samples using RNAqueous™-Micro Total RNA Isolation Kit (Ambion, AM1931); 25 ng of RNA was used to synthesize cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA, 4368814). Quantification of target gene expression was performed using Qiagen QuantiTect Primer Assay for LPA 1 (Hs_LPAR1_1_SG, QT00021469), LPA 2 (Hs_LPAR2_2_SG, QT01851318), LPA 3 (Hs_LPAR3_1_SG, QT00092932), PECAM (Hs_PECAM1_1_SG, QT0008172) and normalized to 18 s (Hs_RRN18S_1_SG, QT00199367). Gene expression analysis was performed using BioRad CFX96 Touch Read-Time PCR Detection System. Each sample was evaluated as an average of a triplicate.
Immunohistochemistry
Vessels were isolated from tissue and immediately placed in zinc formalin buffer followed by paraffin embedding. Immunohistochemistry was performed by the Children's Hospital of Wisconsin Histology Core. Sections were cut at 4 μm and placed on poly-L-Lysine coated slides, which were then dried at 45°C overnight and stored in room temperature prior to IHC testing. Slides were then loaded onto the Leica Bond Max immunostainer. All samples were de-waxed prior to staining on the instrument. Antibodies required antigen retrieval pretreatment as follows: LPA 1 receptor H1 (20) and LPA 3 receptor H1(20) citrate buffer at pH 6 and CD31 H2(10) EDTA retrieval. Antibodies used: LPA 1 receptor (Abcam, ab166903, 1:100), LPA 3 receptor (LS-Bio, LS-A1014/40949, 1:200) and CD31 (Agilent, DAKO, M0823, 1:100). All antibodies were detected and visualized using Leica Bond Polymer Refine Detection System (DS9800) with the addition of a DAB enhancer (AR9432), using the modified versions of the MODF protocol installed by Leica filed service engineers. Slides were removed from the immunostaining platform, dehydrated, cleared and coverslipped with synthetic mounting media. Omission of the primary antibody served as a negative control. Slides were scanned with a NanoZoomer HT slide scanner (Hamamatsu, Japan).
Fluorescence detection of mitochondrial H 2 O 2 in human microvessels
To evaluate mitochondrial H 2 O 2 release in human arterioles challenged with LPA (10 μM, 30 min), Mito Peroxy Yellow 1 (MitoPY1) was used (Dickinson and Chang, 2008) . As previously described, vessels were cannulated in a chamber containing HEPES buffer warmed to 37°C and pH 7.4 (Kadlec et al., 2017) . The same buffer containing the fluorescent MitoPY1 probe (10 μM, 1 h) was used to perfuse vessels intraluminally. Fluorescence was imaged using a krypton/argon lamp fluorescent microscope (model TE 200 Nikon Eclipse) or X-cite FIRE LED microscope (model Olympus IX73) and an excitation/emission wavelength of 488 nm/530-590 nm before administration of LPA, 30 min after, and every minute for 5 min once max flow (Pressure Gradient of 100 cmH 2 O) was applied. Relative fluorescence intensity (arbitrary units) was measured using ImageJ (NIH) by subtracting background fluorescence from vessels fluorescence. The % increase in fluorescence intensity from static values after 5 min of max flow (% increase to flow) was compared between intact control and other treatments of vessels. Endothelial contribution to the fluorescence signal was assessed by denuding a subset of vessels. Briefly, vessels were isolated, cleaned and one end was cannulated onto a glass micropipette. Vessels were then equilibrated for 30 min at 37°C. Once equilibrated, 4 mL of air was passed through the vessel to dislodge the endothelium. After denudation, the loose end of the vessel was cannulated and experimental protocol for fluorescence detection of mitochondrial H 2 O 2 was continued. Viability of the arterioles was assessed by the following protocol: arterioles were allowed to equilibrate without flow for 5-10 min; after equilibration, 0.3 nM of ET-1 was used to constrict the vessels; the vessels needed to retain constriction for 10 min after which 100 μM of ACh was added followed by 100 μM of papaverine to assess the vessels' ability to dilate. Vessels that did not constrict to ET-1 or did not dilate to papaverine were excluded from the study. After completion of the protocol, arterioles were removed from the glass cannulas and snap-frozen in liquid nitrogen and stored at À80°C until further processing. Denudation efficiency was assessed by measuring expression of the endothelial marker, PECAM, using RT-qPCR.
Statistical analysis
All data are expressed as mean ± SEM with statistical significance threshold set at P < 0.05. For vascular studies, data are expressed as a % of maximal dilation from ET-1-induced constriction, where 100% represents full relaxation to the maximal diameter noted throughout the experiment. To compare flow-response relationship, a two-way ANOVA was used with pressure gradient (or dose-response to SNP or ACh) and treatment as parameters. When a significant difference was observed between curves (P < 0.05), responses at individual pressure gradients were compared using a Holm-Sidak multiple comparison test. To compare the concentration of SNP required to cause 50% of the maximum response (EC 50 ), a three-parameter nonlinear regression using least squares (ordinary) fit analysis was performed. One-way ANOVA was used to compare fluorescence (MitoPY1 probe) in microvessels before and after interventions. Wilcoxon test was used to compare PECAM expression in control versus denuded arterioles. All analyses were performed using GraphPad Prism 7.04 (GraphPad Software, San Diego, CA, USA) and SAS 9.4 (SAS, Cary, NC, USA) with statistical significance defined at P < 0.05.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
Discarded adipose tissue (subcutaneous and visceral) was collected from a total of 111 patients, six with CAD and 105 categorized as non-CAD. Patient demographics are detailed in Table 1 . Mean diameter prior to constriction, after constriction and concentration of ET-1 needed to achieve desired constriction across all experiments are summarized in Table 2 .
LPA shifts the mediator of FID from NO to H 2 O 2 in human arterioles
To confirm NO as the baseline mediator of FID in human adipose arterioles, vessels were treated with either L-NAME or Peg-Cat in the absence of LPA. The presence of L-NAME blunted the peak FID, but Peg-Cat had no effect on the dilation in untreated arterioles ( Figure 1A) . Treatment of non-CAD vessels with LPA preserved the magnitude of dilation but shifted the meditator of FID to H 2 O 2 (dilation inhibited by Peg-Cat) ( Figure 1B) . In contrast to its inhibitory effect on dilation in untreated vessels ( Figure 1A) , pre-incubation with L-NAME in LPA-treated vessels did not inhibit but instead slightly increased dilation at lower levels of flow ( Figure 1B ).
Arterioles treated with LPA also showed reduced dilation to an endothelium-dependent dilator (ACh) with differences in peak value ( Figure 1C ) and EC 50 (Àlog EC 50 : 6.83 ± 0.18 for control and Àlog EC 50 : 5.86 ± 0.44 for LPA, P < 0.05). To determine whether treatment with LPA affected endotheliumindependent arteriolar responses, dose-response curves to SNP (a direct NO donor) were performed in LPA-treated and untreated arterioles. No significant differences were observed in EC 50 (Àlog EC 50 : 7.03 ± 0.24 for control and Àlog EC 50 : 7.03 ± 0.23 for LPA, Figure 1D ) or peak values ( Figure 1D ). Additionally, because two videomicroscopy studies (control vs.
L-NAME or Peg-Cat) were often performed in succession on a single arteriole, we also assessed whether LPA treatment had a time-dependent effect on the overall magnitude of FID and found no differences in these time control experiments (Supporting Information Figure S1 ).
Signalling through LPA 1 receptor leads to the loss of NO-mediated FID in non-CAD human arterioles
We next examined which receptor might be responsible for the LPA-induced shift in the mediator of FID. Figure 2A shows that non-CAD arterioles treated with the LPA 1/3 antagonist, Ki16425, maintained NO-mediated FID after the acute LPA challenge. Peg-Cat, which inhibits FID after LPA treatment alone, had no effect on the dilation after combined treatment with LPA and Ki16425 (Figure 2A ). Blocking LPA 2 ( Figure 2B ) did not prevent the shift to H 2 O 2 -mediated dilation (Peg-Cat abolished FID). To ensure that the shift to H 2 O 2 -mediated dilation is not caused by the LPA 2 receptor antagonist alone, we tested the effects of the antagonist in the absence of LPA and observed no effect on NO-mediated dilation (Supporting Information Figure S2 ). H2L5186303 is an LPA 2 receptor antagonist when used at a nM concentrations, but at higher, μM concentrations, it can also act as an LPA 3 receptor antagonist (Fells et al., 2009) . We, therefore, tested a higher concentration of H2L5186303 (10 μM) before LPA challenge. As before, Peg-Cat inhibited the dilation (% maximal dilation at Mean diameter prior to constriction, post constriction and concentration of ET-1 needed to achieve desired constriction across all vascular experiments. n = number of patients. Comparisons were made between studies without LPA (greyed out) and corresponding studies with LPA + intervention. *P < 0.05 for L-NAME versus LPA + L-NAME, control versus Ki16425 + LPA, L-NAME versus Ki16425 + LPA + L-NAME, control versus H2L5186303 + LPA, L-NAME versus H2L5186303 + LPA + L-NAME.
100 cm H 2 O: H2L5186303 + LPA 80.6 ± 4.6, n = 3 vs. H2L5186303 + LPA + Peg-Cat À26.3 ± 1.2, n = 3) while L-NAME had no effect (Supporting Information Figure S3 ).
LPA 1 and LPA 2 but not LPA 3 receptors are expressed in human adipose microvessels
To investigate which LPA receptors are responsible for the arteriolar effects of LPA, we examined LPA 1-3 receptor expression in intact human adipose arterioles. As shown in Figure 3 , transcripts for LPA 1 and LPA 2 receptors but not LPA 3 were abundantly detectable by PCR. The pattern of expression was not different between CAD versus non-CAD tissue for any of the three receptors ( Figure 3A) . Because our functional studies using an LPA 2 receptor antagonist demonstrated no involvement of that receptor in the LPA-induced shift of the mediator of FID, the remaining expression studies focused on LPA 1 and LPA 3 receptors. Western blot analysis was performed on LPA 1 and LPA 3 receptors to examine protein levels. Figures 3B show robust detection of LPA 1 in both CAD and non-CAD vessels as well as HUVECs and left ventricle of the human heart, which was used as a positive control. The LPA 3 receptor was not detected in arterioles from patients with or without CAD, and only faint expression was detected in HUVECs ( Figure 3C ). The LPA 3 receptor was also detected in human heart samples with some additional non-specific bands. Immunohistochemical studies of human non-CAD arterioles also demonstrated strong staining for LPA 1 ( Figure 4A ) but not LPA 3 receptors ( Figure 4B) . A similar pattern of expression was observed in CAD arterioles, with the LPA 1 receptor but not LPA 3 being expressed in the vessels. Sections of human pancreas were used to verify efficiency of the LPA 3 receptor antibody (Supporting Information Figure S6 ). Immunohistochemical analyses appeared to localize LPA 1 receptor expression predominantly to VSMCs, with little to no staining in ECs ( Figure 4A,B) . To further investigate whether LPA receptors are expressed in human ECs, we examined the expression of LPA 1 and LPA 3 receptors in two types of cultured endothelial cells, HUVECs and HMVECs. There was robust expression of LPA 1 receptors in HUVECs and HMVECs as shown in Figure 5A ,B respectively. LPA 3 was detected in HUVECs, albeit at a low level, and no expression of the LPA 3 receptor was detected in HMVECs ( Figure 5C ,D respectively). Two different antibodies (see Methods section) targeting different epitopes were used to ensure validity of the expression patterns of the LPA 3 receptor in arterioles and
Figure 1
Effects of LPA on the mediator of FID in non-CAD human adipose arterioles. (A) L-NAME inhibits peak FID in control vessels, but Peg-Cat has no effect. (B) In vessels treated with LPA (10 μM, 30 min), Peg-Cat significantly reduces peak FID. Presence of L-NAME in LPA-treated vessels significantly improved FID but only at the 20 cmH 2 O of pressure gradient. (C) Dilation to ACh is significantly decreased in arterioles treated with LPA in comparison to control arterioles. (D) Dilation to SNP is not different between control and LPA-treated vessels. *P < 0.05 versus control at specific pressure gradients, # P < 0.05 versus control at 20 cmH 2 O pressure gradient (L-NAME curve), P = NS between 1st and 2nd curve at each pressure gradient; n is shown in parentheses.
cultured endothelial cells. In both cases, we found the expression of the receptor to be lower or absent across different preparations. Supporting Information Figure S4 shows a lower expression of the LPA 3 receptor in two types of cultured endothelial cells, with robust expression in the heart using Abc antibody, while Supporting Information Figure S5 validates lower expression of LPA 3 receptor in non-CAD arterioles and immunohistochemical preparations using LSBio antibody. These data suggest that LPA 1 receptors are expressed in the arteriolar medial layer and, to a much lower extent in vascular endothelium, even though expression is robust in culture microvascular endothelial cells. LPA 3 receptors are minimally expressed in human coronary arterioles or cultured endothelial cells.
Mitochondria are the source of LPA-induced H 2 O 2
We previously showed that the mitochondria are the main source of flow-induced H 2 O 2 release in CAD arterioles (Liu et al., 2003; Freed et al., 2014) . To assess whether LPA specifically increases mitochondria-derived H 2 O 2 in non-CAD arterioles, we applied mitoPY1, a fluorescent probe specifically designed to image mitochondrial H 2 O 2 in our cannulated arteriole experiments. Figure 6A shows representative images of the cannulated vessels in the bright field, under static conditions and after 5 min of maximal (100 cmH 2 O) flow, in intact untreated and LPA-treated (10 μmol·L À1 , 30 min) and as well as denuded untreated and LPA-treated arterioles.
Quantification of the relative fluorescence intensity is shown in Figure 6B . Untreated, non-CAD vessels (control) showed minimal increases in fluorescence as compared to LPA-treated, non-CAD arterioles. Denuded controls and LPA-treated arterioles showed a trend towards an increase in fluorescence in comparison to intact control vessels ( Figure 6B ). More importantly, denuded arterioles treated with LPA do not show a significant increase in fluorescence signal in response to flow when compared to intact arterioles treated with LPA. Denudation efficiency was analysed by examining expression of endothelium-specific target protein, PECAM (Supporting Information Figure S7 ). To further test the mitochondria as the source of H 2 O 2 , we measured FID in the presence of Rotenone, an electron transport chain complex I inhibitor that has been shown previously to reduce mtH 2 O 2 production and block FID in arterioles from patients with CAD (Liu et al., 2003) . Figure 6C shows that rotenone significantly reduces FID after LPA treatment. Rotenone alone has been known not to affect either the overall magnitude of the dilation or the mediator of FID (Freed et al., 2014; Beyer et al., 2016) .
Discussion
The major novel findings of the present study are as follows: first, acute (30 min) exposure of non-CAD human arterioles to 10 μM LPA induces a switch in the mechanism of FID from NO to H 2 O 2 , recapitulating the CAD phenotype;
Figure 2
LPA acts through LPA receptors to shift the mediator of FID. (A) Treatment of arterioles with Ki16425, LPA 1 and LPA 3 receptor inhibitor, prior to LPA challenge preserves NO-mediated FID as indicated by L-NAME but not Peg-Cat inhibitable dilation (n = 8, 7 and 7 respectively). (B) Inhibition of LPA 2 receptor with H2L5186303 prior to LPA challenge had no effect on LPA-induced shift to H 2 O 2 -mediated FID (n = 6, 6 and 6 respectively).
(C) Experimental timeline. *P < 0.05 control.
second, LPA 1 receptor is involved in the LPA-induced shift to H 2 O 2 -mediated FID; third, LPA 1 and LPA 2 receptors but not LPA 3 are expressed in human arterioles from patients without CAD; and fourth, mitochondria are the source of LPA-induced H 2 O 2 production. These findings show for the first time that elevated concentrations of LPA act in an LPA 1 receptor-dependent manner to induce an arteriolar endothelial phenotype characteristic of that seen in patients with CAD.
LPA receptor-dependent effects on the mediator of FID
Elevated LPA is associated with vascular pathology and is known to exert multiple harmful effects on vascular endothelial (Rizza et al., 1999; Panetti et al., 2000; van Nieuw Amerongen et al., 2000; Panetti, 2002; Panetti et al., 2004; Lin et al., 2006; Avraamides et al., 2007; Lin et al., 2007) and smooth muscle (Hayashi et al., 2001; Panchatcharam et al., 2008) integrity. In particular, studies have shown that LPA can lead to increased levels of ROS either independent of (Brault et al., 2007; Staiculescu et al., 2014) or in conjunction with decreased eNOS expression (Chen et al., 2012) , effectively decreasing endothelium-dependent dilation to bradykinin in porcine arterioles (Chen et al., 2012) . We extend these findings and demonstrate that acutely elevated levels of LPA disrupt endothelium-dependent FID in human arterioles by shifting the mechanism away from NO to mtH 2 O 2 .
There was a noticeable improvement in dilation at lower pressure gradients after L-NAME treatment ( Figure 1B ), which could potentially be ascribed to elimination of uncoupled eNOS-derived reactive nitrogen/oxygen species, which scavenge the dilatory ROS (Yang et al., 2009) or the fact that quenching any remaining NO releases the block on mtH 2 O 2
Figure 3
Reverse-transcriptase PCR analysis of LPA receptors in arterioles. (A) RNA from intact arterioles from patients with and without CAD was analysed for transcript levels of LPA 1 , LPA 2 and LPA 3 receptors. The presence of CAD had no effect on expression of LPA 1 receptor or LPA 2 receptor but no target sequences for LPA 3 receptor were detected in either non-CAD or CAD (n.d. -not detected). CAD expression is represented as fold change from non-CAD. The number of transcripts was normalized to 18 s in the same sample. (B) Western blot quantification of LPA 1 receptor in non-CAD versus CAD arterioles. (C) No quantification was possible for the LPA 3 receptor. Representative images for each receptor show two non-CAD and two CAD patients, HUVECs and human heart left ventricle. GAPDH used for loading control. A.U. -arbitrary units, (n) indicates number of subjects.
( Beyer et al., 2017) . LPA significantly reduced dilation to ACH, potentially by increasing intracellular ROS, which can compromise endothelial NO bioavailability. This observation is consistent with others from our lab (Beyer et al., 2016; Durand et al., 2016) where ACh-induced dilation is more sensitive to ROS than FID. LPA did not negatively affect smooth muscle responses to NO as indicated by lack of difference in dilation to SNP between treated and untreated vessels. Additionally, the amount of constrictor agent, ET-1, did not vary between control versus LPA-treated vessel. Presence of LPA and L-NAME did require more ET-1. Although LPA has been described to affect vessel tone (Tokumura et al., 1981; Tokumura et al., 1995) , our data argue against either a direct vasoconstrictor or vasodilator effect of LPA, but rather suggest that LPA-induced production of the dilator H 2 O 2 might be responsible for the higher dose required for constriction since presence of Peg-Cat (H 2 O 2 scavenger) eliminated that effect. To our knowledge, this is also the first study examining the function and expression of LPA 1-3 receptors in human resistance-size arterioles. Functional data from vessels treated with LPA 2 receptor antagonist indicated that unlike LPA 1 and/or LPA 3 , LPA 2 fails to shift the mediator of FID. Instead, LPA 1 receptor appears to be mechanistically involved. qPCR analysis showed robust expression of LPA 1 and LPA 2 but not LPA 3 , with no difference between arterioles from subjects with and without CAD. Protein analysis from human arterioles identified LPA 1 receptor as the dominant isoform with no difference between CAD and non-CAD phenotype. LPA 3 receptor protein was detected in human heart, albeit at a 
Figure 6
Intracellular source of H 2 O 2 in arterioles after LPA challenge. (A) Representative images of cannulated vessels perfused intraluminally with mito peroxy yellow (MitoPY1) under intact control (n = 6), intact LPA treatment (n = 6), denuded control (6) and denuded LPA treatment (6). Images show bright field, static (no flow) and 5 min of flow (100 cm H 2 O gradient). (B) Quantification of mitochondrial H 2 O 2 expressed as % increase in fluorescence from baseline (static) to 5 min of maximal (100 cmH 2 O) flow. *P < 0.05 intact control versus intact LPA, intact LPA versus denuded control and intact LPA versus denuded LPA. (C) Source of dilator H 2 O 2 was determined by incubating vessels with a mitochondria-targeted inhibitor, rotenone (1 μM) for 30 min after LPA challenge. n = 10 and 7 respectively. *P < 0.05 versus LPA. Bar for all images = 20 μm.
lower level than LPA 1 receptor. Faint expression of LPA 3 receptor protein was also detected in HUVECs. Absence or minimal expression of LPA 3 has been observed in endothelial (Lee et al., 2000; Lin et al., 2007; Ruisanchez et al., 2014) and smooth muscle (Dancs et al., 2017) cells from animal models or cultured vascular human cell lines. We confirmed previously published data using HUVEC and HMVECs. Immunohistochemistry not only confirmed robust staining for LPA 1 in comparison to LPA 3 in arterioles but also localized the signal predominantly to SMC with little to no expression in arteriolar endothelial cells.
Lack of pronounced expression of LPA receptors, in particular LPA 1 receptor, in arteriolar tunica intima was an unexpected finding. Prior findings in animal models and endothelial cell cultures show majority of LPA effects being mediated through LPA 1 receptor (Gobeil et al., 2003; Brault et al., 2007; Cui, 2011; Ruisanchez et al., 2014; Dancs et al., 2017) . Additionally, we and others observe strong protein and RNA expression in cultured endothelial cells (Lin et al., 2007; Ptaszynska et al., 2010; Ren et al., 2011) . Collectively, we interpret these findings to indicate that LPA 1 are likely present in human arteriolar endothelial cells, albeit at a much lower level of expression than in SMC, yet sufficient to cause an LPA-induced shift in the mediator of FID. An alternative explanation of these findings is that LPA acts on SMC to release a factor that acts on the endothelium in a way that changes the mediator of FID. Future efforts should be centred on evaluating the LPA-mediated bidirectional crosstalk between these two vascular layers as well as cellspecific expression of these receptors in their native vascular environment.
The source of ROS production is not identified in most LPA-related vascular studies, but mitochondria and NADPH Oxidases (NOX) are prominent candidates in ECs (Widlansky and Gutterman, 2011; Breton-Romero and Lamas, 2014; Panieri and Santoro, 2015) . We tested whether mitochondria were a source of H 2 O 2 under LPA challenge using the mitochondrial complex I inhibitor, rotenone. Rotenone reduced dilation to the same extent as the general H 2 O 2 scavenger, Peg-Cat. A mitochondrial source of H 2 O 2 was further suggested using a mitochondria-specific fluorescent probe. In some settings, NOX is the source of LPA-stimulated ROS (Lin et al., 2013) . We cannot exclude a role for NOX in FID following LPA treatment, which could occur via ROS-induced ROS release where small amounts of NOX-related ROS stimulate release of mitochondrial ROS or vice versa (Zinkevich and Gutterman, 2011; Zinkevich et al., 2017) . In fact, a recent study showed LPA 1 and LPA 3 receptor-dependent activation of PLC, PKC and eventual stimulation of NOX to generate ROS in cell culture model (Lin et al., 2013) . Our current findings align with previously published observations demonstrating that the mitochondria are the main source of the dilator H 2 O 2 in human arterioles affected by CAD (Freed et al., 2014; Beyer et al., 2016; Kadlec et al., 2017) . Acute LPA exposure thus establishes a CAD phenotype in non-CAD arterioles.
Details of the signalling pathway by which LPA induces the shift to H 2 O 2 -mediated FID through LPA 1 necessitate further investigation. One compelling possibility is the welldocumented crosstalk between Rho-and Rac-dependent cytoskeleton rearrangement and ROS signalling. In fact, recent publication from Chandra and colleagues, using real-time measurements, demonstrated that increasing levels of LPA or down-regulating expression of LPP3, one of the main enzymes that degrades LPA, leads to dysfunctional mitochondria with increased production of superoxide in a Rho-and ERK-dependent manner (Chandra et al., 2018) . LPA induces changes to the endothelial cytoskeleton in an LPA 1 receptor-dependent manner by phosphorylating myosin light chain (Wu et al., 2015) , forming stress fibres and RhoA-and Rac-dependent cytoskeletal rearrangements (Siess et al., 1999) . Studies examining mitochondrial dynamics identified LPA, amongst other glycerol-based lipids, to regulate mitochondrial fission and fusion (Baba et al., 2014; Ha and Frohman, 2014; Frohman, 2015) . Together, these studies suggest that LPA may affect mitochondrial structural dynamics, loss of which results in increase in mitochondria-derived ROS production. Future studies will focus on examining the potential downstream mediators of the observed LPA-induced effects.
Preliminary studies from our laboratory examined the ability of arterioles to recover and regain NO-mediated FID by incubating LPA-treated arterioles in fresh media lacking LPA. Even overnight (~18 h) incubation in fresh media of arterioles treated with LPA for 1 h did not restore NO as the dilator (Supporting Information Figure S8 ). We therefore suggest that once the LPA-activated signalling cascade is initiated, damage is prolonged, predisposing the vasculature to further damage caused by increased ROS. This observation sheds light on an exciting clinical opportunity, whereupon assessing the expression of enzymes responsible for both synthesis and degradation of LPA may prove to be a novel preventive or early intervention strategy. In fact, a risk allele leading to decreased expression of LPP3, the enzyme that degrades LPA, has been identified by genome-wide association studies in nearly 80% of the population, and shown to be highly predictive of CAD, independent of traditional risk factors (Schunkert et al., 2011; Erbilgin et al., 2013) . Therefore, the effects of LPA revealed in this study may affect a large portion of the population and represent an underappreciated pathophysiological pathway in cardiovascular disease.
Study limitations
We obtained samples that are surgical discards and are therefore unable to control for all patient characteristics. Vessels are isolated from different fat depots, but we have not observed major differences in vascular responses to flow as evident in our previous publications. The mechanism of FID seems to be preserved across these vascular beds, including the phenotypic switch in tissue acquired from patients with clinically diagnosed CAD. The non-CAD arterioles are isolated from individuals whose clinical profiles (medications, demographics, etc) are not fully known. However, we do acquire information on prior diagnosis of CAD and presence of risk factors. By defining our non-CAD cohort strictly as having one or no CV risk factors, we limit the degree to which non-CAD samples are classified falsely. Females represent most of our non-CAD vessels. Our sample sizes are too small to detect sex differences in vascular function within and between the phenotypes, but this should be addressed in a larger study. Although we used receptor antagonists well-documented in the literature, it is possible that they may be non-specific or have off-target effects. We addressed such possibilities by testing antagonists for different receptors as well as examining receptor expression. In regard to LPA 1 receptor expression, although we and others show expression in cultured endothelial cells, we were unable to detect the receptor in arteriolar ECs using immunohistochemical approach. This suggests at least three possibilities. (i) Arteriolar ECs may have LPA 1 receptors sufficient to elicit the switch, but the immunohistochemical approach is not sufficiently sensitive to detect them; (ii) the epitope recognized by the antibody is not accessible in IHC preparations; or (iii) LPA may be acting on LPA 1 receptor in SMC and stimulate release of a factor that acts on the endothelium in a way that changes the mediator of FID. Additionally, we have made attempts to knockdown LPA 1 receptor using siRNA at two different concentrations with incubations periods as long as 48 h (time limit for isolated arterioles). However, these attempts have been unsuccessful. siRNA transfected arterioles do not show a decrease in LPA 1 receptor protein expression. Lastly, because we did not perform histological analysis on all the arterioles used throughout our studies, we cannot exclude the possibility of denudation in some of our vessels. However, because FID is an endothelium-dependent process (in the presence or absence of LPA), maintained dilation suggests that the endothelium was intact during our studies.
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article. Figure S4 LPA 3 receptor protein expression immunoblot analysis using a second LPA 3 receptor-targeting antibody.Human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC) showed low LPA 3 receptor protein expression, while human heart samples (from three different non-CAD subjects) revealed robust expression of the protein. GAPDH was used as loading control. Figure S5 LPA 3 receptor protein expression in intact non-CAD arterioles using LSBio antibody. (A) Immunoblot analyses for LPA 3 receptor from vessels isolated from individuals without CAD. GAPDH used for loading control. (B) Immunohistochemistry analyses for LPA 3 receptor in vessels from an individual without CAD. CD31 staining used to identify endothelial cell layer. Specificity of the antibody was determined by removal of the primary antibody (not shown). Bar for all images = 100 μm. Figure S7 Assessment of the denudation efficiency in arterioles. RNA from intact and denuded arterioles from patients without CAD was analyzed for PECAM transcript levels. Denuded expression is represented as fold change from intact. The number of transcripts was normalized to 18 s in the same sample. Figure S8 Prolonged effects of LPA on the mediator of FID. (A) Peg-Cat continued to inhibit FID after LPA stimulation (10 μM, 1 hr) and 16-18 hours of fresh media recovery period. L-NAME had no effect. (B) Experimental timeline.
